Open Access Highly Accessed Open Badges Research

Efficacy of Leuprolide Acetate 1-Month Depot for Central Precocious Puberty (CPP): Growth Outcomes During a Prospective, Longitudinal Study

Peter A Lee12*, E Kirk Neely3, John Fuqua2, Di Yang4, Lois M Larsen4, Cynthia Mattia-Goldberg4 and Kristof Chwalisz4

Author Affiliations

1 The Milton S. Hershey Medical Center, College of Medicine, Pennsylvania State University, Hershey, PA 17033, USA

2 Section of Pediatric Endocrinology and Diabetology, James Whitcomb Riley Hospital for Children, School of Medicine, Indiana University, Indianapolis, IN 46202, USA

3 Division of Pediatric Endocrinology and Diabetes, Room G313, Stanford University Medical Center, Stanford, CA 94305, USA

4 Abbott Laboratories, 200 Abbott Park Road, Abbott Park, IL 60064, USA

For all author emails, please log on.

International Journal of Pediatric Endocrinology 2011, 2011:7  doi:10.1186/1687-9856-2011-7

Published: 12 July 2011



Gonadotropin-releasing hormone analogs (GnRHa) are the treatment of choice for CPP. We investigated growth in GnRHa-naïve subjects, treated with leuprolide acetate 1-month depot for CPP.


This prospective, open-label study had a long-term, observational, follow-up period. Forty-nine females and 6 males were enrolled. Leuprolide acetate depot was administered intramuscularly every 28 days. Height and growth rate during and after treatment until adulthood were measured.


Among 30 of 49 females having an adult height (AH) measurement, 29 had target heights available (mean = 163.8 cm) and 27 had pretreatment predicted adult heights (PAHs; mean = 157.4 cm). After treatment, the mean AH at mean age 21.8 years [range 13.7-26.7 years] was 162.5 cm, a mean height gain over baseline PAH of 4.0 cm. The mean height standard deviation score was -0.1 at AH.


Treatment of CPP with leuprolide acetate 1-month depot had beneficial effects on growth rate and preservation of AH.

Trial Registration NCT00660010